H.C. Wainwright lowered the firm’s price target on Immunic (IMUX) to $8 from $10 and keeps a Buy rating on the shares. The firm adjusted the company’s share count post the Q3 report.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMUX:
- Immunic, Inc. Reports Q3 2025 Financial Results
- Immunic’s Promising Market Potential: Buy Rating Backed by Vidofludimus Calcium’s Efficacy, Safety, and Strategic Financial Path
- Immunic reports Q3 EPS (13c), consensus (18c)
- Datadog, Trade Desk upgraded: Wall Street’s top analyst calls
- Immunic initiated with a Buy at Roth Capital